News Sentiment

NVCT sentiment intelligence

Nuvectis Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.14 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+4.3% over one week, +38.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 4.3% Price confirming higher
Trend fit Trend active 38.5% over four weeks
Fair value 125.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 25
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingView 4
simplywall.st 4
MT Newswires 3
Moomoo 2
Investing.com 2
Cantech Letter 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 11
Deals and strategy 3
Analyst action 2
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
GlobeNewswire Direct company coverage

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The company intends to use the net proceeds to advance the development

Tone
Negative 40/100
Event
Market update
Published
30 Jun 2026 04:40
Source
GlobeNewswire
TipRanks Direct company coverage

Nuvectis Pharma Suspends Equity Offering Program Under Agreement

Nuvectis Pharma (NVCT) has announced the suspension of its equity offering program with Leerink Partners LLC. Initially established in May 2025 to allow for periodic sales of common stock, the company decided on June 29, 2026, to reduce the offering size to $5 million and halt fu

Tone
Negative 40/100
Event
Market update
Published
30 Jun 2026 04:10
Source
TipRanks
Investing.com Nigeria Direct company coverage

Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com

Nuvectis Pharma announced the pricing of a $100 million underwritten public offering of 5,000,000 shares of common stock at $20.00 per share. The company plans to use the net proceeds to advance development programs for NXP100, NXP200, and NXP900, hire additional personnel, and c

Tone
Negative 32/100
Event
Market update
Published
30 Jun 2026 02:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Nuvectis locks in $100M from 5 million-share stock sale

Nuvectis Pharma announced the pricing of an underwritten public offering of 5,000,000 common shares at $20.00 per share, aiming to raise $100 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Proceeds will

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 02:39
Source
Stock Titan
Stock Titan Direct company coverage

Nuvectis Pharma Commences Public Stock Offering

Nuvectis Pharma (Nasdaq: NVCT) announced an underwritten public offering of common stock to raise capital for the development of its NXP100, NXP200, and NXP900 programs, hiring, and general corporate purposes. This equity financing, with Cantor acting as sole book runner, may lea

Tone
Negative 30/100
Event
Market update
Published
29 Jun 2026 19:39
Source
Stock Titan